CD154 peptides and methods of inhibiting CD40 interactions with CD154
US11130795B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Feb 3, 2017 |
| Grant date | Sep 28, 2021 |
| Priority date | — |
| Expiry date | Feb 6, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/1774
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides methods and materials for treating and preventing autoimmune diseases. In particular, the present invention relates to the discovery that small peptides are capable of interacting with CD40, thereby interfering with the ability of CD40 to interact with CD154, which is important in inflammation. The present invention also relate to the use of such peptides in reducing the inflammatory response, and in particular, the autoimmune inflammatory response. The present invention also relates to the use of such short peptides to prevent or reverse autoimmune disease, and particular, diabetes, in individuals suffering from such disease. It also relates to methods and materials for detecting T-cells that express CD40 (Th40 cells). Also provided are kits for reducing inflammation, treating autoimmune diseases, or detecting Th40 cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.